Movement Alert｜MEDBOT-B Intraday Rise 6.16%, First Buy Rating from Da Hua Securities Combined with Historic First Half-Year Profit

Market Focus08-11

On August 11, MEDBOT-B rose 6.16% in regular trading, trading at 24.78 HKD/share, with turnover of approximately 96.47 million HKD.

On the news front, Da Hua Securities initiated coverage on the company with a \"Buy\" rating and a target price of 29 HKD, noting the company possesses the most comprehensive surgical robot product portfolio in the industry, spanning laparoscopic, orthopedic, vascular, and urological applications. Its flagship Toumai and Honghu systems have received market approval in China and the EU.

Concurrently, the company previously issued a positive profit alert, projecting H1 net profit of RMB 28-40 million versus a net loss of RMB 115 million in the same period last year, marking its first-ever half-year profitability. Revenue surged approximately 200%-230% year-over-year, with Toumai robot overseas revenue growing over 450% and overall gross margin improving by more than 15 percentage points. Haitong International attributed the turnaround to revenue growth, margin expansion, and enhanced expense management working in concert.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138950350?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-11 13:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138950350","market":"us","top_or_hot":-1,"title":"Movement Alert｜MEDBOT-B Intraday Rise 6.16%, First Buy Rating from Da Hua Securities Combined with Historic First Half-Year Profit","media":"Market Focus","content":"<p><p>On August 11, MEDBOT-B rose 6.16% in regular trading, trading at 24.78 HKD/share, with turnover of approximately 96.47 million HKD.</p><p>On the news front, Da Hua Securities initiated coverage on the company with a \\\"Buy\\\" rating and a target price of 29 HKD, noting the company possesses the most comprehensive surgical robot product portfolio in the industry, spanning laparoscopic, orthopedic, vascular, and urological applications. Its flagship Toumai and Honghu systems have received market approval in China and the EU.</p><p>Concurrently, the company previously issued a positive profit alert, projecting H1 net profit of RMB 28-40 million versus a net loss of RMB 115 million in the same period last year, marking its first-ever half-year profitability. Revenue surged approximately 200%-230% year-over-year, with Toumai robot overseas revenue growing over 450% and overall gross margin improving by more than 15 percentage points. Haitong International attributed the turnaround to revenue growth, margin expansion, and enhanced expense management working in concert.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜MEDBOT-B Intraday Rise 6.16%, First Buy Rating from Da Hua Securities Combined with Historic First Half-Year Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜MEDBOT-B Intraday Rise 6.16%, First Buy Rating from Da Hua Securities Combined with Historic First Half-Year Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-11 13:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 11, MEDBOT-B rose 6.16% in regular trading, trading at 24.78 HKD/share, with turnover of approximately 96.47 million HKD.</p><p>On the news front, Da Hua Securities initiated coverage on the company with a \\\"Buy\\\" rating and a target price of 29 HKD, noting the company possesses the most comprehensive surgical robot product portfolio in the industry, spanning laparoscopic, orthopedic, vascular, and urological applications. Its flagship Toumai and Honghu systems have received market approval in China and the EU.</p><p>Concurrently, the company previously issued a positive profit alert, projecting H1 net profit of RMB 28-40 million versus a net loss of RMB 115 million in the same period last year, marking its first-ever half-year profitability. Revenue surged approximately 200%-230% year-over-year, with Toumai robot overseas revenue growing over 450% and overall gross margin improving by more than 15 percentage points. Haitong International attributed the turnaround to revenue growth, margin expansion, and enhanced expense management working in concert.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02252","symbol_name":"微创机器人-B","start_time":0,"source_url":"","article_id":"1138950350","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138950350","pubTimestamp":1786424629,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 11, MEDBOT-B rose 6.16% in regular trading, trading at 24.78 HKD/share, with turnover of approximately 96.47 million HKD.On the news front, Da Hua Securities initiated coverage on the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02252":"微创机器人-B"},"translate_title":"走势提醒|MEDBOT-B盘中上涨6.16%，大华证券首次给予买入评级，上半年盈利创历史新高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02252":1},"content_text":"On August 11, MEDBOT-B rose 6.16% in regular trading, trading at 24.78 HKD/share, with turnover of approximately 96.47 million HKD.On the news front, Da Hua Securities initiated coverage on the company with a \\\"Buy\\\" rating and a target price of 29 HKD, noting the company possesses the most comprehensive surgical robot product portfolio in the industry, spanning laparoscopic, orthopedic, vascular, and urological applications. Its flagship Toumai and Honghu systems have received market approval in China and the EU.Concurrently, the company previously issued a positive profit alert, projecting H1 net profit of RMB 28-40 million versus a net loss of RMB 115 million in the same period last year, marking its first-ever half-year profitability. Revenue surged approximately 200%-230% year-over-year, with Toumai robot overseas revenue growing over 450% and overall gross margin improving by more than 15 percentage points. Haitong International attributed the turnaround to revenue growth, margin expansion, and enhanced expense management working in concert.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138950350","isCrawlerRequest":true}